$1.20 Earnings Per Share Expected for Alnylam Pharmaceuticals, Inc. (ALNY) This Quarter

Paterniano Del Favero
Agosto 11, 2017

Athenahealth Incorporated (NASDAQ:ATHN) had a decrease of 0.08% in short interest. Its down 0.08% from 8.15M shares previously. The daily trading volume average remained 1.07 million shares over the course of 3 months. (NASDAQ:ALNY) has risen 33.54% since August 11, 2016 and is uptrending. It has underperformed by 12.66% the S&P500.

06/21/2017 - Alnylam Pharmaceuticals, Inc. had its "overweight" rating reiterated by analysts at Piper Jaffray. Northern Trust reported 80,852 shares stake. Baillie Gifford & Co now controls 1,395,596 shares worth $111,313,000. O'Brien Timothy John also sold $363,654 worth of athenahealth, Inc (NASDAQ:ATHN) shares. About 16,665 shares traded. Prelude Lc reported 1,100 shares. Current price level places the company's stock about -6.3% from the 52-week high and 159.53% away from the 52-week low. The Firm also offers Epocrates and other point-of-care mobile applications. The Firm delivers majority of its service offerings through a single instance of cloud software, athenaNet.

Investors sentiment increased to 1.12 in 2016 Q4. Its down 0.25, from 1.02 in 2016Q3.

Altrinsic Glob Limited Liability Co owns 102,700 shares. 123 funds opened positions while 351 raised stakes. Ubs Asset Management Americas holds 20,111 shares. Principal Group holds 0% or 12,851 shares. Ares Mngmt Ltd Liability Company has invested 0.62% in Fifth Street Finance Corp. Paloma Prtnrs Management Co has 25,538 shares.

Foyston Gordon & Payne Inc decreased Medtronic Plc (MDT) stake by 15.79% reported in 2016Q4 SEC filing. Ordinary Shares (NYSE:MDT). Invesco Ltd reported 8.59 million shares. Manufacturers Life Insur The owns 2,374 shares for 0% of their portfolio. Zacks Investment Research's EPS calculations are an average based on a survey of analysts that cover Alnylam Pharmaceuticals. (NASDAQ:ALNY) rating on Thursday, October 6. The firm earned "Buy" rating on Thursday, February 9 by Needham. The brokerage now has a $131.00 target price on the biopharmaceutical company's stock, up from their previous target price of $110.00. On October 7 the company was downgraded from " to "Equal-weight" by. The rating was upgraded by JP Morgan to "Overweight" on Friday, March 11. As per Monday, December 19, the company rating was maintained by Chardan Capital Markets.

Investors might also notice that three month ago the Buy recommendations (9) outnumbered Sell recommendations (0). Its down 0.02, from 1.02 in 2016Q3. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. 35 funds opened positions while 64 raised stakes. 2,220 are held by Nordea Inv Ab. Amalgamated National Bank & Trust owns 0.02% invested in Alnylam Pharmaceuticals, Inc.

Press coverage about Alnylam Pharmaceuticals (NASDAQ:ALNY) has been trending somewhat positive recently, Accern Sentiment Analysis reports.

"Leerink Swann Weighs in on Alnylam Pharmaceuticals, Inc.'s Q2 2017 Earnings (ALNY)" was reported by Week Herald and is the property of of Week Herald. (NASDAQ:ALNY). Blackrock Fund Advisors holds 0.01% in Alnylam Pharmaceuticals, Inc. Bank & Trust Of America Corporation De invested 0% in Alnylam Pharmaceuticals, Inc. Shares for $74,030 were sold by CHUKWU EMEKA on Tuesday, May 30. Baker Bros Advsr Limited Partnership accumulated 11,340 shares or 0% of the stock. Sectoral Asset Mgmt Inc has invested 0.08% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Signpost Lp holds 1.52% or 33,065 shares in its portfolio. Rhumbline Advisers owns 90,383 shares. Independent Portfolio Consultants reported 2,280 shares or 0.17% of all its holdings. Aviva Public Limited Liability Corporation holds 48,022 shares or 0.01% of its portfolio.

Based on the latest notes released to investors, 3 analysts have issued a rating of "buy", 7 analysts "outperform", 8 analysts "hold", 0 analysts "underperform" and 0 analysts "sell".

Ratings analysis reveals 57% of Alnylam Pharma's analysts are positive.

05/15/2017 - Alnylam Pharmaceuticals, Inc. had its "outperform" rating reiterated by analysts at Cowen. As per Monday, July 17, the company rating was maintained by Oppenheimer. The rating was initiated by Citigroup on Tuesday, September 6 with "Neutral". Vanguard Group Inc. now owns 5,660,213 shares of the biopharmaceutical company's stock valued at $290,086,000 after buying an additional 200,890 shares during the period. (NASDAQ:ALNY) earned "Buy" rating by Jefferies on Friday, October 23. Credit Suisse Group reissued a "hold" rating and set a $50.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 9th. The brokerage set an "outperform" rating and a $99.00 price target on the biopharmaceutical company's stock.

On October 7 the stock rating was downgraded to "Equal-weight" from " in a report issued by Morgan Stanley. Chardan Capital Markets maintained the stock with "Buy" rating in Wednesday, November 30 report. Jefferies maintained the stock with "Buy" rating in Thursday, October 6 report.

Since January 1, 0001, it had 2 insider buys, and 3 insider sales for $17.81 million activity. The insider Mason Michael sold $656,250.

In other news, major shareholder Sanofi purchased 297,501 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 31st.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE